TRLV Trulieve Cannabis (TRLV) Q2 FY26 earnings call
Trulieve reported Q2 FY26 results marked by federal rescheduling of medical cannabis to Schedule III and its uplisting to the NYSE. The company demonstrated strong performance in its medical-only business, driven by operational efficiencies and strategic investments in high-growth markets like Georgia and Texas. Despite a temporary supply shortage in Georgia and a net loss due to deconsolidation, Trulieve is focused on expanding access, growing its customer base, and leveraging its strong balance sheet for future opportunities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.